Every material Form 8-K Eloxx Pharmaceuticals, Inc. has filed with the SEC since June 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Eloxx Pharmaceuticals expanded its board from five to six directors on October 19, 2026, appointing Geno J. Germano, a former Pfizer group president, as an independent director. On October 20, the company also announced the appointment of T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer and finalized the design of its Phase 2 EXPRESS trial of exaluren in ADPKD. The filing contains no financial results or guidance.
On October 19, 2026, the board increased its size from five to six and appointed Geno J. Germano to the new seat, with a term ending at the 2027 annual meeting.
Germano received an option grant for up to 13,587 shares at an exercise price of $12.50, vesting monthly over 24 installments.
T.R. Srinivas, M.D., was appointed Senior Vice President and Chief Medical Officer, as announced October 20, 2026.
The EXPRESS Phase 2 trial is designed to enroll about 60 adults; first patient dosing is expected in the third quarter of 2027 and topline data in the first half of 2029.
Eloxx Pharmaceuticals reported a second-quarter 2026 net loss of $4.5 million, up from $1.9 million a year earlier, as research and development and general and administrative costs rose. The company completed a $66.0 million underwritten public offering in June 2026 and moved its listing to the Nasdaq Capital Market, and it says its cash will fund operations into mid-2028, which strengthens the balance sheet but adds new shares outstanding for existing holders.
Net loss for the quarter ended June 30, 2026 was $4.5 million, compared with $1.9 million for the same quarter of 2025.
The June 2026 underwritten offering had gross proceeds of $66.0 million and net proceeds of about $58.3 million.
Cash and cash equivalents were $62.0 million at June 30, 2026, which the company expects to fund operations into mid-2028.
Eloxx Pharmaceuticals completed a 1-for-11 reverse stock split of its common stock, effective 5:00 p.m. Eastern Time on May 29, 2026, and reduced authorized common shares from 500,000,000 to 100,000,000. The company also appointed Stephen W. Webster and Nina Kjellson to its board, filling vacancies and reducing the board from six to five directors.
Every 11 shares of common stock combined into one share; trading on a split-adjusted basis expected on the OTC Pink Market on June 1, 2026
Authorized common shares reduced from 500,000,000 to 100,000,000
Stephen W. Webster and Nina Kjellson appointed to the board on May 27, 2026; each received an option grant for up to 13,587 shares
Prefunded warrant exercises of 2,500,000 shares occurred on April 27, 2026, and an exchange of those shares for prefunded warrants on May 27, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Eloxx Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →